Journal of Clinical Medicine · 2024 · 30 citations · 134 references
Life SciencesNeurobiologyNeuroscienceDementiaGene TherapyNeurodegenerationAlzheimer DiseaseAmyloid FormationNeurodegenerative DiseasesNeurodegenerative DisordersNeuroinflammationTau PathologyAmyloid Beta AggregationAmyloid Beta-targeted TherapyInhibition Of Amyloid FormationNeuroinflammation In Alzheimer DiseaseNeuroinflammation ModulationStem Cell-based TherapyTau-targeted TherapyTherapeutic Targeting Of Amyloid
Alzheimer's disease (AD) causes a significant challenge to global healthcare systems, with limited effective treatments available. This review examines the landscape of novel therapeutic strategies for AD, focusing on the shortcomings of traditional therapies against amyloid-beta (Aβ) and exploring emerging alternatives. Despite decades of research emphasizing the role of Aβ accumulation in AD pathogenesis, clinical trials targeting Aβ have obtained disappointing results, highlighting the complexity of AD pathophysiology and the need for investigating other therapeutic approaches. In this manuscript, we first discuss the challenges associated with anti-Aβ therapies, including limited efficacy and potential adverse effects, underscoring the necessity of exploring alternative mechanisms and targets. Thereafter, we review promising non-Aβ-based strategies, such as tau-targeted therapies, neuroinflammation modulation, and gene and stem cell therapy. These approaches offer new avenues for AD treatment by addressing additional pathological hallmarks and downstream effects beyond Aβ deposition.
134
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Dale Schenk, Robin Barbour, Whitney Dunn et al. · Nature · 1999 · 3.2K citations
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Jeff Sevigny, Ping Chiao, Thierry Bussière et al. · Nature · 2016 · 3.1K citations
New insights into the genetic etiology of Alzheimer’s disease and related dementias
Céline Bellenguez, Fahri Küçükali, Iris E. Jansen et al. · Nature Genetics · 2022 · 2.5K citations · Full text
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Stephen Salloway, Reisa A. Sperling, Nick C. Fox et al. · New England Journal of Medicine · 2014 · 2K citations · Full text
Medicine, Neurology, Pharmacology +17